Display options
Cite
Diandé S, Badoum G, Combary A, et al. Multidrug-Resistant Tuberculosis in Burkina Faso from 2006 to 2017: Results of National Surveys. Eur J Microbiol Immunol (Bp). 2019;9(1):23-28doi: 10.1556/1886.2018.00029.
Diandé, S., Badoum, G., Combary, A., Zombra, I., Saouadogo, T., Sawadogo, L. T., Nébié, B., Gnanou, S., Zigani, A., Ouédraogo, S. M., Diallo, A., Kaboré, S., & Sangaré, L. (2019). Multidrug-Resistant Tuberculosis in Burkina Faso from 2006 to 2017: Results of National Surveys. European journal of microbiology & immunology, 9(1), 23-28. https://doi.org/10.1556/1886.2018.00029
Diandé, Souba, et al. "Multidrug-Resistant Tuberculosis in Burkina Faso from 2006 to 2017: Results of National Surveys." European journal of microbiology & immunology vol. 9,1 (2019): 23-28. doi: https://doi.org/10.1556/1886.2018.00029
Diandé S, Badoum G, Combary A, Zombra I, Saouadogo T, Sawadogo LT, Nébié B, Gnanou S, Zigani A, Ouédraogo SM, Diallo A, Kaboré S, Sangaré L. Multidrug-Resistant Tuberculosis in Burkina Faso from 2006 to 2017: Results of National Surveys. Eur J Microbiol Immunol (Bp). 2019 Feb 06;9(1):23-28. doi: 10.1556/1886.2018.00029. eCollection 2019 Mar 18. PMID: 30967972; PMCID: PMC6444799.
Copy Download .nbib Format: NLM
Share it on

Eur J Microbiol Immunol (Bp). 2019 Feb 06;9(1):23-28. doi: 10.1556/1886.2018.00029. eCollection 2019 Mar 18.

Multidrug-Resistant Tuberculosis in Burkina Faso from 2006 to 2017: Results of National Surveys.

European journal of microbiology & immunology

Souba Diandé, Gisèle Badoum, Adjima Combary, Issaka Zombra, Tandaogo Saouadogo, Léon T Sawadogo, Bayéma Nébié, Saïdou Gnanou, Adama Zigani, Seydou Mohamed Ouédraogo, Adama Diallo, Seydou Kaboré, Lassana Sangaré

Affiliations

  1. Programme National de Lutte contre la Tuberculose, Ministère de la Santé, Ouagadougou, Burkina Faso.
  2. Université Ouaga-I Pr Joseph Ki-Zerbo, Unité de Formation en Sciences de la Santé, Ouagadougou, Burkina Faso.
  3. CHU Yalgado Ouédraogo, Département de Médecine, Services de Pneumologie, Ouagadougou, Burkina Faso.
  4. Centre National de Lutte Antituberculeuse, Ministère de la Santé, Ouagadougou, Burkina Faso.
  5. Direction de la Protection de la Santé et de la Population, Ministère de la Santé, Ouagadougou, Burkina Faso.
  6. CHU Yalgado Ouédraogo, Département des laboratoires, Service de Bactériologie-Virologie Ouagadougou, Burkina Faso.

PMID: 30967972 PMCID: PMC6444799 DOI: 10.1556/1886.2018.00029

Abstract

SETTING: A survey of the prevalence of drug-resistant tuberculosis (DR-TB) in new and previously treated patients (PTPs) was performed in Burkina Faso from 2016 to 2017.

DESIGN: In this cross-sectional survey, a structured questionnaire was administered to eligible smear-positive patients in all 86 diagnostic and treatment centers of the country to collect their socio-demographic characteristics and medical histories. Their sputa were tested using the

RESULTS: Of the 1140 smear-positive patients enrolled, 995 new and 145 PTPs were positive for MTB complex by Xpert. Of these, 2.0% (20/995, 95% confidence interval (CI): 1.1-2.9) of the new cases and 14.5% (95% CI: 14.2-20.2) of the PTPs were resistant to rifampicin; 83% of them has multidrug-resistant tuberculosis (MDR-TB). None were pre-extensively drug-resistant TB (pre-XDR-TB) or XDR-TB. Only the previous treatment was significantly associated with rifampicin resistance,

CONCLUSION: Similar to global trends, rifampicin resistance was significantly higher in patients with prior TB treatment (14.5%) than in naïve patients (2.0%). These percentages are slightly below the global averages, but nonetheless suggest the need for continued vigilance. Extending the use of Xpert testing should strengthen the surveillance of DR-TB in Burkina Faso.

Keywords: Burkina Faso; Xpert MTB/RIF; prevalence; rifampicin resistance; survey; tuberculosis

Conflict of interest statement

Conflict of Interest The authors declare no conflict of interest.

References

  1. Emerg Infect Dis. 2007 May;13(5):776-8 - PubMed
  2. Bull World Health Organ. 2007 May;85(5):387-90; discussion 391-4 - PubMed
  3. Rev Lat Am Enfermagem. 2007 Sep-Oct;15 Spec No:762-7 - PubMed
  4. S Afr Med J. 2007 Nov;97(11 Pt 3):1120-8 - PubMed
  5. PLoS One. 2009;4(5):e5561 - PubMed
  6. Microb Drug Resist. 2009 Sep;15(3):217-21 - PubMed
  7. Emerg Infect Dis. 2010 May;16(5):840-2 - PubMed
  8. Int J Tuberc Lung Dis. 2010 Nov;14(11):1424-9 - PubMed
  9. Am J Public Health. 2011 Apr;101(4):654-62 - PubMed
  10. Emerg Infect Dis. 2013 Mar;19(3):478-80 - PubMed
  11. PLoS One. 2013 Aug 01;8(8):e70763 - PubMed
  12. Pulm Med. 2013;2013:235190 - PubMed
  13. PLoS One. 2013 Nov 06;8(11):e77712 - PubMed
  14. BMC Public Health. 2015 Jun 20;15:572 - PubMed
  15. PLoS One. 2016 Apr 07;11(4):e0152694 - PubMed
  16. BMC Med. 2016 Nov 3;14(1):160 - PubMed
  17. Eur Respir J. 2017 Mar 22;49(3): - PubMed
  18. Infect Drug Resist. 2017 Mar 13;10:91-96 - PubMed
  19. PLoS One. 2017 Sep 25;12(9):e0185105 - PubMed
  20. J Natl Med Assoc. 2018 Feb;110(1):88-91 - PubMed
  21. BMC Infect Dis. 2018 Apr 2;18(1):149 - PubMed
  22. Eur J Microbiol Immunol (Bp). 2018 Aug 16;8(3):91-94 - PubMed
  23. Wkly Epidemiol Rec. 1997 Mar 21;72(12):81-7 - PubMed

Publication Types